Skip to main
PGEN

Precigen (PGEN) Stock Forecast & Price Target

Precigen (PGEN) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 33%
Buy 67%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Precigen is a commercial-stage biopharmaceutical company with a strong focus on developing innovative precision medicines for the treatment of immuno-oncology, autoimmune disorders, and infectious diseases. The company has a diverse pipeline of products, including Papzimeos, which has shown promising results in clinical trials and is expected to be a franchise product for the company. Additionally, Precigen has filed for a Marketing Authorization Application with the EMA and is planning to expand the drug's indications to the pediatric population. Financially, Precigen has reported a strong 4Q25 with sales of $3.4M and a net loss of $0.04 per diluted share. The company is expected to see rapid growth in 1Q26 with sales expected to exceed $18M. Furthermore, with sufficient cash reserves and potential growth from Papzimeos, Precigen has the financial means to continue its research and development programs, including the promising PRGN-2009. Overall, the company's portfolio, growth potential, and strong financial position make it a favorable investment opportunity for long-term growth.

Bears say

Precigen is expected to have strong sales for Papzimeos in 1Q26 due to a significant increase in product sales, driven by higher-than-expected adoption and a favorable reimbursement environment. However, there are risks associated with clinical, regulatory, commercial, partnership, financial, and intellectual property factors that could impact the company's performance and the price of its stock in the long-term. While the company's stock price may receive a temporary boost, due to an increase in price target from $9 to $10, these risks should be considered carefully before making any investment decisions.

Precigen (PGEN) has been analyzed by 3 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 67% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Precigen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Precigen (PGEN) Forecast

Analysts have given Precigen (PGEN) a Buy based on their latest research and market trends.

According to 3 analysts, Precigen (PGEN) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Precigen (PGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.